COMPANY NEWS


Zydus Lifesciences Ltd
BSE Code 532321 ISIN Demat INE010B01027 Book Value (₹) 145.11 NSE Symbol ZYDUSLIFE Div & Yield % 0.61 Market Cap ( Cr.) 100,321.53 P/E * 37.33 EPS * 26.71 Face Value (₹) 1
* Profit to Earning Ratio
* Earning Per Share
Zydus launches Mirabegron ER Tablets in US market Back
(22 Apr 2024)

Zydus Lifesciences announced the launch of Mirabegron Extended-Release Tablets, 25 mg in the US market. The company had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg (USRLD: Myrbetriq® Extended-Release Tablets). Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market and is prepared to launch Mirabegron Extended-Release Tablets, 50mg imminently.

Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ, India.